CN109498788A - It is a kind of to treat turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle and preparation method thereof - Google Patents
It is a kind of to treat turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle and preparation method thereof Download PDFInfo
- Publication number
- CN109498788A CN109498788A CN201811603646.3A CN201811603646A CN109498788A CN 109498788 A CN109498788 A CN 109498788A CN 201811603646 A CN201811603646 A CN 201811603646A CN 109498788 A CN109498788 A CN 109498788A
- Authority
- CN
- China
- Prior art keywords
- turbid
- china
- pill
- stagnation
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006187 pill Substances 0.000 title claims abstract description 48
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 47
- 206010062717 Increased upper airway secretion Diseases 0.000 title claims abstract description 43
- 208000026435 phlegm Diseases 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 57
- 241000132012 Atractylodes Species 0.000 claims abstract description 28
- 239000011148 porous material Substances 0.000 claims abstract description 28
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 27
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 26
- 235000008397 ginger Nutrition 0.000 claims abstract description 26
- 241001672694 Citrus reticulata Species 0.000 claims abstract description 25
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 23
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 23
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 23
- 229940010454 licorice Drugs 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 12
- 239000006071 cream Substances 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000706 filtrate Substances 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 53
- 241000234314 Zingiber Species 0.000 claims description 24
- 241000202807 Glycyrrhiza Species 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 10
- 238000005498 polishing Methods 0.000 claims description 3
- 239000008103 glucose Substances 0.000 abstract description 45
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 36
- 239000008280 blood Substances 0.000 abstract description 35
- 210000004369 blood Anatomy 0.000 abstract description 35
- 208000024891 symptom Diseases 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 14
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 13
- 230000001976 improved effect Effects 0.000 abstract description 11
- 102000051325 Glucagon Human genes 0.000 abstract description 8
- 108060003199 Glucagon Proteins 0.000 abstract description 8
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 8
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract description 8
- 229960004666 glucagon Drugs 0.000 abstract description 8
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 244000273928 Zingiber officinale Species 0.000 abstract 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 description 17
- 210000002784 stomach Anatomy 0.000 description 15
- 230000000291 postprandial effect Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- 206010067484 Adverse reaction Diseases 0.000 description 9
- 230000006838 adverse reaction Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 8
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 210000003141 lower extremity Anatomy 0.000 description 6
- 230000035922 thirst Effects 0.000 description 6
- 108010075254 C-Peptide Proteins 0.000 description 5
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 5
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 206010018473 Glycosuria Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000005059 dormancy Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000534017 Saururus chinensis Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000254223 Syntexis Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- -1 pulvis Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a kind of treat diabetes B stagnation of turbid phlegm in middle-JIAO card and turbid tune sugar-pill of middle drop and preparation method thereof, comprising: 270~290g of Rhizoma Alismatis, 260~275g of umbellate pore furgus, 260~275g of PORIA from Yunnan of China, 15~25g of licorice, 260~275g of fried atractylodes, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, 10~20g of CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China 120g, Ramulus Cinnamomi 60g and ginger slice.Rhizoma Alismatis, umbellate pore furgus, PORIA from Yunnan of China and all medicines of Radix Glycyrrhizae are put into baking oven first, dries, it is spare to be ground into fine powder after mixing；Then fried atractylodes, rhizoma atractylodis macrocephalae, citrus chachiensis hortorum, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China, Ramulus Cinnamomi and all medicine mixing and water addings of ginger slice are decocted three times, decocting liquid merges filtration, and filtrate is concentrated into clear cream, then mixes with fine powder and squeeze pill after mixing cream, polishes drying.The present invention and the turbid clinical symptoms for adjusting sugar-pill that can significantly improve T2DM stagnation of turbid phlegm in middle-JIAO card patient of middle drop, and glucose -lipid metabolism disorder can be improved, improve islet function, mitigates insulin resistance, glucagon and blood glucose fluctuation degree are reduced, does not occur any toxic side effect during clinical observation.
Description
Technical field
The invention belongs to pharmaceutical technology fields, and in particular to it is a kind of treat diabetes B stagnation of turbid phlegm in middle-JIAO card and it is middle drop it is turbid
Adjust sugar-pill and preparation method thereof.
Background technique
TCM investigation person thinks to quench one's thirst non-solely " yin deficiency is scorching " opinion, sums up that " yin deficiency is that glycosuria is pathogenetic basic；The deficiency of vital energy
It is the crux of diabetes protracted course of disease；Deficiency of both qi and yin is important department's stage of diabetes；Yin-yang deficiency is the certainty of diabetes de-velopment
Trend；Stagnation of turbid phlegm in middle-JIAO is the MAIN SOILS that diabetes are sprouted；Stagnation of liver-QI with deficiency of the spleen is its very important interpretation of the cause, onset and process of an illness；Blood stasis is to cause glycosuria
The main reason for sick complication；Damp and hot retardance is deterioration of a case during diabetes de-velopment " diabetes mellitus pathogenesis summarize.Advocate
Under the commander of "and" theory, diagnosis and treatment and specific prescription and medication is taken to organically combine, from starting with for improvement " soil ", Lai Shixian at all
Regulating and controlling blood sugar it is steady up to standard.
Have no in the prior art have both and in Remedies for diabetes with turbid function, Chinese patent CN101757228A
A kind of Chinese materia medica preparation for treating diabetes is disclosed, which is made of following medicinal materials, and 2-40 parts of the root bark of white mulberry, saururus chinensis
2-40 parts, Cortex Eucommiae 2-40 parts of mountain, 2-40 parts of Radix Salviae Miltiorrhizae, 2-40 parts of radix paeoniae rubra, the Chinese medicine of the patent disclosure only has clearing heat and nourishing yin, promotes the production of body fluid
It moisturizes, resolving phlegm lowering turbidity, the function of activating microcirculation and removing stasis medicinal.
Summary of the invention
To achieve the above object, the present invention is provided to quench the thirst with the turbid, hypoglycemic of middle drop, diabetes B stagnation of turbid phlegm in middle-JIAO is cured mainly
" and middle turbid tune sugar-pill of drop " compound pill of card and preparation method thereof.
" the odd disease opinion of Plain Questions " cloud: " fertile institute's hair, this person, which must count, eats sweet and refreshing and more fertilizer.Overeating greasy food bringing about internal heat is sweet
Person enables swelling of REN ZHONG, therefore its gas overflow, switchs to quench one's thirst ", wet essential resistance of turbid is strongly fragrant and change heat, and it decocts bright body fluid and sees dry, wet essential resistance of turbid,
Though dry is but not intended to drink.Damp-heat gluing each other, disorder in ascending and descending, clean air do not rise, and foul smell does not drop, and mechanism of qi loses Yu Xuanzhan, then indigestion and loss of appetite uncomfortable, head
Weight is faint.As XUE Sheng-bai is said: " humidifier category sun is bright, Taiyin channels person is in the majority.Middle gas the disease being located in YANG position actually is bright, and the middle deficiency of vital energy is then sick too
Yin ", that is, refer in the real element of gas report the partially prosperous person of yang-energy, then it is evil with humidifying, the bright stomach of the disease being located in YANG position symptoms include thirst without desire to drink, bitter taste, stick it is greasy, four
Limb is heavy, yellowish fur.In conjunction with tongue vein, ginseng is closed in the four methods of diagnosis, and dialectical is MIDDLE ENERGIZER DAMPNESS-HEAT.
Based on above content, the turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle is treated the present invention provides a kind of,
It is prepared using following Chinese medicine material: 270~290g of Rhizoma Alismatis, 260~275g of umbellate pore furgus, 260~275g of PORIA from Yunnan of China, licorice
15~25g, 260~275g of fried atractylodes, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China 120g, Ramulus Cinnamomi 60g and ginger slice 10~
20g.The fried atractylodes are bran fried atractylodes, and rhizoma atractylodis macrocephalae is stir-baked RHIZOMA ATRACTYLDIS MACROCEPHALAE in bran.
Further, described a kind of turbid tune sugar-pill of drop that treat diabetes B stagnation of turbid phlegm in middle-JIAO card and middle, in following
Medicine raw material is prepared: 271~279g of Rhizoma Alismatis, 261~266g of umbellate pore furgus, 261~266g of PORIA from Yunnan of China, 16~19g of licorice,
261~267g of fried atractylodes, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, 11~14g of CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China 120g, Ramulus Cinnamomi 60g and ginger slice.
Further, described a kind of turbid tune sugar-pill of drop that treat diabetes B stagnation of turbid phlegm in middle-JIAO card and middle, in following
Medicine raw material is prepared: 281~289g of Rhizoma Alismatis, 268~274g of umbellate pore furgus, 268~274g of PORIA from Yunnan of China, 21~24g of licorice,
269~274g of fried atractylodes, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, 16~19g of CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China 120g, Ramulus Cinnamomi 60g and ginger slice.
Further, described a kind of turbid tune sugar-pill of drop that treat diabetes B stagnation of turbid phlegm in middle-JIAO card and middle, in following
Medicine raw material is prepared: Rhizoma Alismatis 280g, umbellate pore furgus 267g, PORIA from Yunnan of China 267g, licorice 20g, fried atractylodes 268g, rhizoma atractylodis macrocephalae
260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China 120g, Ramulus Cinnamomi 60g and ginger slice 15g.
Further, described a kind of turbid tune sugar-pill of drop that treat diabetes B stagnation of turbid phlegm in middle-JIAO card and middle, in following
Medicine raw material is prepared: Rhizoma Alismatis 270g, umbellate pore furgus 260g, PORIA from Yunnan of China 260g, licorice 15g, fried atractylodes 260g, rhizoma atractylodis macrocephalae
260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China 120g, Ramulus Cinnamomi 60g and ginger slice 10g.
Further, described a kind of turbid tune sugar-pill of drop that treat diabetes B stagnation of turbid phlegm in middle-JIAO card and middle, in following
Medicine raw material is prepared: Rhizoma Alismatis 290g, umbellate pore furgus 275g, PORIA from Yunnan of China 275g, licorice 25g, fried atractylodes 275g, rhizoma atractylodis macrocephalae
260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China 120g, Ramulus Cinnamomi 60g and ginger slice 20g.
The flat stomach of fried atractylodes invigorating the spleen in the present invention, eliminating dampnessization is turbid, and rising Yang dissipates heresy；Rhizoma atractylodis macrocephalae invigorating the spleen to dry, benefiting qi for promoting production of blood, be for
Monarch drug in a prescription, clear " the high original of book on Chinese herbal medicine " meaning: " Rhizoma Atractylodis Macrocephalae is then used in all desire tonifying spleens, and all spleens to be transported then use rhizoma atractylodis, be intended to mend fortune mutually and, then mutually and and
With, such as mending mostly fortune, less, then Rhizoma Atractylodis Macrocephalae is more and rhizoma atractylodis are few, transports and mends less more, then rhizoma atractylodis are more and Rhizoma Atractylodis Macrocephalae is few, though product have two, actually one "；
Citrus chachiensis hortorum, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China qi-regulating eliminating dampness, promoting the circulation of qi middle benefit gas resolving sputum, with the source of exhausted phlegm retention metaplasia；Umbellate pore furgus, PORIA from Yunnan of China, Rhizoma Alismatis Chang Xiangxu
For with collaboration Li Shui, the detumescence of energy clearing damp and promoting diuresis, wherein most strong with umbellate pore furgus Li Shui effect, Rhizoma Alismatis is slightly better than PORIA from Yunnan of China.Because of cloud
Poria cocos is sweet light flat, enters heart spleen kidney channel, can invigorating spleen and relieving mental stress.It can complementary energy rush down, rush down in have benefit, not stagnant wet, the diuresis of nourishing the heart and spleen
Do not hurt just, mend benefit and row, giving consideration to both the incidental and fundamental, performance is gentle, actually sharp water key medicine.Umbellate pore furgus is sweet light flat, returns kidney bladder meridian, but not as good as cloud
The benefit of Poria cocos.Rhizoma Alismatis is sweet light cold, returns kidney bladder meridian, the heat cold in nature that can let out kidney and bladder, and damp-heat in lower-JIAO person is especially suitable for, total
For ministerial drug；Ramulus Cinnamomi temperature yang transforming qi Li Shui, is for adjutant；Ginger slice helps full side with eliminating dampness and eliminating phlegm；Licorice harmonizing the spleen and stomach, and in
Gas is to help transporting；It is altogether to make medicine.All medicines match, and we are always with invigorating the spleen to dry, and resolving phlegm lowering turbidity is to treat big method, and spleen originally has transporting water
Wet function, spleen it is strong it is then wet go phlegm to disappear, wet to go, clear sun is so incensed that with a liter hair, internal ascending or descending movement of vital Qi restores normally, to control to reach
Treat the purpose of diabete.Stagnation of turbid phlegm in middle-JIAO, when sugared for first with drying damp and strengthening spleen, resolving phlegm lowering turbidity and middle tune.With middle drop turbid tune sugar-pill system stomach
Siberian cocklebur soupization cut out, the party with legislation, with for use, reconcile go up and down, reconciliation internal organs, principle-method-recipe-medicines are intricately woven together, flexibility
It cuts out curative for effect.Adjust it is dirty support it is dirty, spleen pancreas with disease work as the spleen pancreas people having the same aspiration and interest.
Appointing in pill, tablet, pulvis, granule, decoction and capsule can be made in the traditional chinese medicine composition of the invention as needed
It anticipates one kind.
It is a kind of to treat the turbid preparation method for adjusting sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle, comprising the following steps:
Step 1: Rhizoma Alismatis, umbellate pore furgus, PORIA from Yunnan of China and all medicines of licorice being put into baking oven, 75 DEG C dry 12 hours, after mixing
It is spare to be ground into 80 mesh fine powders；
Step 2: fried atractylodes, rhizoma atractylodis macrocephalae, citrus chachiensis hortorum, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China, Ramulus Cinnamomi and all medicine mixing and water addings of ginger slice being decocted three times, decocted
Liquid merges filtration, and filtrate is concentrated into clear cream, mixes with step 1 gained fine powder and squeeze pill after mixing cream, polishing is drying to obtain.
Further, it is decocted in step 2 three times specifically: it is 2 hours that the 1st time, which decocts, the 2nd decoction and the 3rd decoction
It is 1 hour.
The beneficial effects of the present invention are:
1, the present invention and turbid the tunes sugar-pill of middle drop include: Rhizoma Alismatis, it is umbellate pore furgus, PORIA from Yunnan of China, licorice, fried atractylodes, rhizoma atractylodis macrocephalae, extensively old
Skin, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China, Ramulus Cinnamomi and ginger slice, we in all medicines share, drying damp and strengthening spleen, resolving phlegm lowering turbidity, primary treatment diabetes B phlegm
Turbid middle resistance card.
2, pass through clinical observation discovery and the turbid clinical condition for adjusting sugar-pill that can significantly improve T2DM stagnation of turbid phlegm in middle-JIAO card patient of middle drop
Shape, while its glucose -lipid metabolism disorder can be improved, improve islet function, mitigate insulin resistance, reduces glucagon and blood glucose
Fluctuation degree, and do not occur any toxic side effect in clinical observation process, application is safe.
3, clinical application 12 years, effect is good, treats 8000 altogether, is almost recovered 2200, effective: 2800, effectively
2200, total effective rate is up to 90%, the low feature of effective in cure good expense compared with similar medicine.
Specific embodiment
Following embodiment is technical solution in order to better illustrate the present invention, rather than limits guarantor of the invention with this
Protect range.
Embodiment 1
It is a kind of to treat the turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle, it is prepared using following Chinese medicine material: building pool
Rush down 271g, umbellate pore furgus 261g, PORIA from Yunnan of China 261g, licorice 16g, fried atractylodes 261g, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China
120g, Ramulus Cinnamomi 60g and ginger slice 11g.
Embodiment 2
It is a kind of to treat the turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle, it is prepared using following Chinese medicine material: building pool
Rush down 279g, umbellate pore furgus 266g, PORIA from Yunnan of China 266g, licorice 19g, fried atractylodes 267g, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China
120g, Ramulus Cinnamomi 60g and ginger slice 14g.
Embodiment 3
It is a kind of to treat the turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle, it is prepared using following Chinese medicine material: building pool
Rush down 281g, umbellate pore furgus 268g, PORIA from Yunnan of China 268g, licorice 21g, fried atractylodes 269g, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China
120g, Ramulus Cinnamomi 60g and ginger slice 16g.
Embodiment 4
It is a kind of to treat the turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle, it is prepared using following Chinese medicine material: building pool
Rush down 289g, umbellate pore furgus 274g, PORIA from Yunnan of China 274g, licorice 24g, fried atractylodes 274g, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China
120g, Ramulus Cinnamomi 60g and ginger slice 19g.
Embodiment 5
It is a kind of to treat the turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle, it is prepared using following Chinese medicine material: building pool
Rush down 280g, umbellate pore furgus 267g, PORIA from Yunnan of China 267g, licorice 20g, fried atractylodes 268g, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China
120g, Ramulus Cinnamomi 60g and ginger slice 15g.
Embodiment 6
It is a kind of to treat the turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle, it is prepared using following Chinese medicine material: building pool
Rush down 270g, umbellate pore furgus 260g, PORIA from Yunnan of China 260g, licorice 15g, fried atractylodes 260g, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China
120g, Ramulus Cinnamomi 60g and ginger slice 10g.
Embodiment 7
It is a kind of to treat the turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle, it is prepared using following Chinese medicine material: building pool
Rush down 290g, umbellate pore furgus 275g, PORIA from Yunnan of China 275g, licorice 25g, fried atractylodes 275g, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China
120g, Ramulus Cinnamomi 60g and ginger slice 20g.
Embodiment 8
It is a kind of to treat the turbid preparation method for adjusting sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle, comprising the following steps:
Step 1: Rhizoma Alismatis 270g, umbellate pore furgus 260g, PORIA from Yunnan of China 260g and licorice 15g are put into baking oven, 75 DEG C dry 12 hours,
It is spare that it is ground into 80 mesh fine powders after mixing；
Step 2: by fried atractylodes 260g, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China 120g, Ramulus Cinnamomi 60g and ginger slice 10g
Mixing and water adding decocts three times, and it is 2 hours that the 1st time, which decocts, and it is 1 hour that the 2nd time, which decocts with the 3rd decoction,.Decocting liquid merges filtration,
Filtrate is concentrated into clear cream, mixes with step 1 gained fine powder and squeezes pill after mixing cream, and polishing, which is drying to obtain, drops turbid tune sugar-pill with middle,
Yield rate is 90%.
Embodiment 9
When being prepared into tablet, tablet yield rate about 90%, 0.3g/ piece.
The turbid tune sugar-pill of of the invention and middle drop is used to treat diabetes B by 10 clinical application embodiment of embodiment, and is passed through
Clinical test achieves preferable curative effect, and related clinical data is as follows:
1. diagnostic criteria
1.1 Western medicine diagnostic criteria diabetes diagnostic criterions: the diagnostic criteria formulated referring to Chinese Medical Association's diabetology branch,
2013 editions " Type 2 Diabetes In China guideline of prevention and treatment ".
(1) diabetes cardinal symptom (mainly including more drinks, diuresis, more foods and syntexis), and (refer to postprandial any time at random
Point) vein blood glucose (VPG) >=11.1mmol/l (200mg/dl)；Or it adds
(2) empty stomach (refer to and do not feed more than 8 hours) vein blood glucose (FPG) level >=7.0mmol/l (126mg/dl)；Or it adds
(3) oral glucose (75g DEXTROSE ANHYDROUS) tolerance test (OGTT) 2h vein blood glucose (2hPG) >=11.1mmol/l
(200mg/dl)。
1.2 TCM syndrome diagnostic criterias:
By Kaifeng division of endocrinology, institute of traditional Chinese medicine there is the above academic title clinician reference of middle rank to be published by Chinese traditional Chinese medicine for 2016
Society publish " treatment of diabetes pandect " and 2007 China Association of Traditional Chinese Medicine " diabetes TCM prevention and cure guide " related content,
And it combines clinical assistance to formulate stagnation of turbid phlegm in middle-JIAO and demonstrate,proves standard:
Stagnation of turbid phlegm in middle-JIAO card: body is fat or overweight, sleepy, the anorexia and loose stool of body weight, thirsty, but amount of drinking water is few.Tongue nature is light
There are indentation or tongue nature light red, whitish tongue is greasy, soft and moderate pulse or cunning etc..
1.3 TCM symptom score quantitative criterias are referring to State Administration of Traditional Chinese Medicine's publication " in 22 professions, 95 diseases
Cure diagnosis and treatment scheme ", by Kaifeng division of endocrinology, institute of traditional Chinese medicine there is the above academic title's clinic doctor of middle rank to score to symptom, respectively
Score registration is carried out in pretherapy and post-treatment.
2. therapeutic scheme:
Collect T2DM patient 66 for meeting the above TCM syndrome diagnostic criteria.Be included in patient by computer random number generator with
Machine is divided into treatment group and control group, and every group each 33, treatment group: male 18, female 15, control group: male 17, female 16；Year
Age is 30 years old minimum, 69 years old maximum.Patient is included under the premise of Primary Care, soothing liver and strengthening spleen tune sugar-pill is given by treatment group, uses
Method dosage: it is oral, 3~4 times on the one, a 6g；Control group gives diabecron sustained-release tablet, and (Guangdong south China medicine company group has
Limit company, national drug standard H44020757) (500mg/ piece), usage and dosage: it is oral, once a day, a 1.0g；12 are treated altogether
Week.
The tcm syndrome curative effect pretherapy and post-treatment to two groups of patients, total effects, clinical symptoms integral, fasting blood-glucose (FPG), meal
2 hours blood glucose (2hPG), glycosylated hemoglobin (HbA1c), empty stomach glucagon, empty stomach C peptide, insulin resistance index afterwards
(HOMA-IR), islet β cell index (HOMA-IS), total cholesterol (TC), triglyceride (TG), high-density lipoprotein
(HDL-C), low-density lipoprotein (LDL-C) is for statistical analysis, and respectively by two groups after treatment 2 weeks, 4 weeks, 8 weeks, 12 weeks
Blood glucose level standard deviation (SDBG), post-prandial glucose excursions amplitude (PPGE), maximum blood glucose fluctuation amplitude (LAGE) counted
Analysis.
3. the standard of curative effect evaluation:
3.1 Syndrome in TCM marquis criterions of therapeutical effect by Kaifeng institute of traditional Chinese medicine there is the division of endocrinology clinician of the above academic title of middle rank to refer to state
" 22 professions, 95 disease Chinese medicine diagnosis and treatment schemes " that the State Administration of Traditional Chinese Medicines, family publishes are determined.
(1) clinical symptoms and sign are obviously improved, and >=70% or more integral reduction is considered as effective.
(2) clinical symptoms and sign take a favorable turn, and integral reduces >=30% or more and is considered as effectively.
(3) clinical symptoms and sign are not improved, even aggravating, integral is reduced to be considered as in vain less than 30% or more.
Note: it is calculated according to Nimodipine method: therapeutic index (n)=[(one post treatment integral of pre-treatment score)/treatment foreset
Point] × 100%.
3.2 disease total effects criterion are had the division of endocrinology clinician of the above academic title of middle rank by Kaifeng institute of traditional Chinese medicine
Determined with reference to " 22 professions, 95 disease Chinese medicine diagnosis and treatment schemes " that State Administration of Traditional Chinese Medicine publishes.
(1) tcm clinical practice symptom and sign are obviously improved, and disease integration reduces >=70%, FPG and 2hPG to normal model
Enclose or FPG and 2hPG value decrease beyond treatment before 40%, HbA1C drop to 6.2% hereinafter, or decrease beyond treatment before
30%, it is considered as above effective.
(2) tcm clinical practice symptom and sign take a favorable turn, and disease integration reduction >=30%, FPG and 2hPG, which is decrease beyond, to be controlled
20% before treatment, but not up to effective standard, HbA1C value decrease beyond 10% before treatment, but not up to effective standard, above
It is considered as effectively.
(3) tcm clinical practice symptom and sign are not improved, even aggravating, disease integration is reduced less than 30%, FPG
And 2hPG is not up to effective standard without decline, or decline, HbA1C value is not up to effective standard without decline, or decline, is considered as above
In vain.
3.3 safety judgment standards: it (uses in 2003 " new Chinese medicine guideline of clinical investigations " about diabetes
Criterion of therapeutical effect) to including after treating in entire therapeutic process, a situation arises for laboratory checking index exception and adverse events, into
Row comprehensive descision.
(1) 1 grade: safety, it is without any adverse reactions.
(2) 2 grades: relatively safety, if any adverse reaction, being not required to do any processing can continue to be administered.
(3) 3 grades: there are safety problems, there is moderate adverse reaction, can continue medication after giving proper treatment.
(4) 4 grades: because adverse reaction stops to test.
4. interpretation of result:
4.1 comparison two groups of patient's overall efficiencies and obvious effective rate statistical result show after the course for the treatment of terminates, treatment group patient
Treatment overall efficiency and treatment obvious effective rate be significantly better than Routine control group patient, there are statistical significances for group difference
(P<0.05).Details are shown in Table 1.
2 weeks, 8 weeks and 12 weeks overall clinical curative effects compare [n (%)] after 1 two groups of patient's treatments of table
Note: distinguish compared with the control group within 2 weeks, 8 weeks and 12 weeks after treatment, * P < 0.05.
The related Indexes Comparison of 4.2 treatments 2,8,12 weeks
The blood glucose level standard deviation (SDBG), post-prandial glucose excursions amplitude (PPGE), maximum blood glucose fluctuation for treating 2 Zhou Hou treatment groups
Amplitude (LAGE) is superior to control group (P < 0.05), statistically significant；Two groups of fasting blood-glucose (FPG), postprandial 2 hours blood
Sugared (2hPG), glycosylated hemoglobin (HbA1c), empty stomach glucagon, empty stomach C peptide, insulin resistance index (HOMA-IR),
It is islet β cell index (HOMA-IS), total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL-C), low close
Spend lipoprotein (LDL-C) no significant difference (P > 0.05).
Fasting blood-glucose (FPG), the postprandial 2 hours blood glucose (2hPG), blood glucose level standard deviation for treating 8 Zhou Hou treatment groups
(SDBG), post-prandial glucose excursions amplitude (PPGE), maximum blood glucose fluctuation amplitude (LAGE), empty stomach glucagon, empty stomach C peptide,
Insulin resistance index (HOMA-IR), islet β cell index (HOMA-IS) are superior to control group (P < 0.05), there is system
Meter learns meaning, two groups of glycosylated hemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG), high-density lipoprotein
(HDL-C), low-density lipoprotein (LDL-C) no significant difference (P > 0.05).
Fasting blood-glucose (FPG), the postprandial 2 hours blood glucose (2hPG), blood glucose level standard deviation for treating 12 Zhou Hou treatment groups
(SDBG), post-prandial glucose excursions amplitude (PPGE), maximum blood glucose fluctuation amplitude (LAGE), empty stomach glucagon, empty stomach C peptide,
Insulin resistance index (HOMA-IR), islet β cell index (HOMA-IS), glycosylated hemoglobin (HbA1c) are superior to
Control group (P < 0.05), statistically significant, two groups of total cholesterol (TC), triglyceride (TG), high-density lipoprotein
(HDL-C), low-density lipoprotein (LDL-C) no significant difference (P > 0.05).
Treatment group and control group total cholesterol (TC), triglyceride (TG), high-density lipoprotein after treatment 12 weeks
(HDL-C), low-density lipoprotein (LDL-C) is superior to after treatment 2 weeks (P < 0.05), statistically significant.
Table 2 treats 2,8,12 weeks related Indexes Comparisons (one)
Note: treatment group and control group compareaP > 0.05,bP < 0.05 compares after organizing interior treatment 12 weeks and after 2 weekscP<0.05。
Table 3 treats 2,8,12 weeks related Indexes Comparisons (two)
Note: treatment group and control group compareaP > 0.05,bP < 0.05 compares after organizing interior treatment 12 weeks and after 2 weekscP<0.05。
The above results illustrate that treatment group and two groups of treatments of control group are effective, but treatment group's blood glucose level after treatment 2 weeks
Standard deviation (SDBG), post-prandial glucose excursions amplitude (PPGE), maximum blood glucose fluctuation amplitude (LAGE) are superior to control group；Treatment 8
Fasting blood-glucose (FPG), postprandial 2 hours blood glucose (2hPG), blood glucose level standard deviation (SDBG), post-prandial glucose excursions amplitude after week
(PPGE), maximum blood glucose fluctuation amplitude (LAGE), empty stomach glucagon, empty stomach C peptide, insulin resistance index (HOMA-IR),
Islet β cell index (HOMA-IS) is superior to control group；The glycosylated hemoglobin (HbA1c) for treating 12 Zhou Hou treatment groups
Also superior to control group, but two groups of total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL-C), low-density lipoprotein
White (LDL-C) no significant difference.This shows improving lipid aspects, and two groups have a good therapeutic effect, (i.e. treatment group) of the invention compared with
Control group is more stable in terms of controlling blood glucose, more longlasting, and the effect especially in terms of islet function improvement becomes apparent from.
4.3. the adverse reaction situation of two groups of patients has 2 patients to occur dizzy, tired after the course for the treatment of terminates, in control group
Tired, nausea and vomiting and of short duration symptom out of strength, 1 generation abdominal pain diarrhea and fash, symptom disappears after giving anti symptom treatment
It loses, adverse reaction rate is 9.09%；Only have 1 in observation group and more slight dizzy, tired, nausea and vomiting and short occur
Symptom temporarily out of strength, does not do specially treated and voluntarily alleviates, other adverse reactions do not occur in addition to this, adverse reaction rate is
3.03%, it is significantly better than the adverse reaction rate (P < 0.05) of Routine control group patient.
5, long-term clinical application result
Clinical application 12 years, effect was good, treats 8000 altogether, is almost recovered 2200, effective: 2800, effective 2200,
Total effective rate is up to 90%.
The clinical symptoms that T2DM stagnation of turbid phlegm in middle-JIAO demonstrate,proves patient can be significantly improved by clinical observation discovery and the turbid tune sugar-pill of middle drop,
Its glucose -lipid metabolism disorder can be improved simultaneously, improve islet function, mitigate insulin resistance, reduce glucagon and blood glucose fluctuation
Degree, and do not occur any toxic side effect in clinical observation process, application is safe.
Six clinical typical case of embodiment
Typical case 1
Mr. Yu, male, has found blood glucose rise when physical examination before 48 years old, patient 4 years, diabetes B is diagnosed as in local hospital, over 4 years
Attention and treatment are not given, and physical examination discovery fasting blood-glucose is in 9mmol/L or so again before 6 months, and postprandial blood sugar is on the left side 13mmol/L
The right side, and there is dry, drink, diuresis, out of strength, the blurred vision in the whole body, the heavy discomfort of giddy, body is fat more, double lower limb and waist and knee acid
Tired, stool is normal, the symptoms such as difficulty falling asleep, and it is dark to look into the tongue nature stasis of blood, tongue body hypertrophy, thin white fur of tongue, deep thready pulse.It takes in of the invention
The whole body is out of strength after pill agent 2 weeks is clearly better, and sleep improves, and continues to take medicine pill 1 month in the present invention, dry, more
Drink improves earlier above, and 5 kilograms of weight loss, whole body improvement out of strength, sleep is clearly better, and sleeps 6-7 hours or so every night.Following the service 2
A month, patient's sings and symptoms of quenching one's thirst were clearly better, and the state of mind is good.
Typical case 2
Hao, male, 49 years old, patient's five years ago found fasting blood-glucose 9mmol/L or so when local hospital physical examination, cured by locality
Institute checks, is diagnosed as " diabetes B ", has body obesity at that time, dry drink the symptoms such as diuresis more, and Hao Xiansheng did not gave weight at that time
Depending on and treatment, weight is gradually reduced over 7 years, and the control of recent fasting blood-glucose is between 7.9-8.9mmol/L, and postprandial blood sugar is in 9.9-
It between 18.2mmol/L, examines symptoms include dry, more drink, diuresis, weight loss then, it is dark to look into the tongue nature stasis of blood, tongue body hypertrophy, and the whole body is weary
Power, lassitude, dim complexion, double lower limb acid is heavy, slight edema, receive dormancy can, enuresis nocturna 2-3 times, big loose stool, is looked by 1-2 times/day
Tongue nature is light, and tongue fur is thin white, deep thready pulse.Medicine pill of the invention is taken after 20 days, the whole body is out of strength, and the symptoms were significantly improved, double lower limb acid
Heavy, slight edema disappears.Of the invention medicine pill 2 months of following the service, look into that the tongue nature stasis of blood is dark, and tongue body hypertrophy is clearly better earlier above, night
Urine 0-1 times, stool molding, quenching one's thirst, the symptoms were significantly improved.
Typical case 3
Zhang, male, physical examination finds blood glucose rise before 41 years old, patient 3 years, is diagnosed as diabetes B, takes hypoglycemic medicine usually
Treatment, less effective, when going to a doctor symptoms include complexion is dim, the puffiness of the eyes, and thirsty drink more, and shortness of breath lazyness speech, double lower limb acid is heavy, waist
Knees soreness, hypogona dism, receive dormancy can, urine frequency, foam urine, stool is normal, and it is light dark to look into tongue nature, tongue body hypertrophy, tongue fur it is thin it is white partially
It is greasy, deep thready pulse.Patient is advised to take medicine pill of the invention 1 week, thirsty, symptoms of drinking are shown in mitigation more；In the following the service present invention
Patient's complexion dimness improves after pill agent January, and the puffiness of the eyes disappears, tell shortness of breath lazyness speech, double lower limb acid it is heavy the symptoms were significantly improved, from
Fasting blood-glucose is surveyed in 6.4mmol/L or so, postprandial 2 hours blood glucose is in 7.5mmol/L or so；Following the service future trouble in drug March of the present invention
Person's complexion turns ruddy, and the puffiness of the eyes disappears, and tells that the heavy symptom of shortness of breath lazyness speech, double lower limb acid disappears, feels preferable.
The embodiment of the above is only used to explain the present invention, the scope of the present invention is not limited, for this technology
It, certainly can be according to technology contents disclosed in this specification, by way of replacing or changing for the technical staff in field
Other embodiments are made easily, therefore all changes and improvements etc. done in the principle of the present invention and process conditions, it should all wrap
It includes in scope of the present invention patent.
Claims (8)
1. a kind of treat the turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle, it is characterised in that: use following Chinese medicine material
It is prepared: 270~290g of Rhizoma Alismatis, 260~275g of umbellate pore furgus, 260~275g of PORIA from Yunnan of China, 15~25g of licorice, fried atractylodes
260~275g, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, 10~20g of CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China 120g, Ramulus Cinnamomi 60g and ginger slice.
2. a kind for the treatment of diabetes B stagnation of turbid phlegm in middle-JIAO card and the turbid tune sugar-pill of middle drop, feature according to claim 1 exist
In: it is prepared using following Chinese medicine material: 271~279g of Rhizoma Alismatis, 261~266g of umbellate pore furgus, 261~266g of PORIA from Yunnan of China, life
16~19g of Radix Glycyrrhizae, 261~267g of fried atractylodes, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China 120g, Ramulus Cinnamomi 60g and ginger slice
11~14g.
3. a kind for the treatment of diabetes B stagnation of turbid phlegm in middle-JIAO card and the turbid tune sugar-pill of middle drop, feature according to claim 1 exist
In: it is prepared using following Chinese medicine material: 281~289g of Rhizoma Alismatis, 268~274g of umbellate pore furgus, 268~274g of PORIA from Yunnan of China, life
21~24g of Radix Glycyrrhizae, 269~274g of fried atractylodes, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China 120g, Ramulus Cinnamomi 60g and ginger slice
16~19g.
4. a kind for the treatment of diabetes B stagnation of turbid phlegm in middle-JIAO card and the turbid tune sugar-pill of middle drop, feature according to claim 1 exist
In: it is prepared using following Chinese medicine material: Rhizoma Alismatis 280g, umbellate pore furgus 267g, PORIA from Yunnan of China 267g, licorice 20g, fried atractylodes
268g, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China 120g, Ramulus Cinnamomi 60g and ginger slice 15g.
5. a kind for the treatment of diabetes B stagnation of turbid phlegm in middle-JIAO card and the turbid tune sugar-pill of middle drop, feature according to claim 1 exist
In: it is prepared using following Chinese medicine material: Rhizoma Alismatis 270g, umbellate pore furgus 260g, PORIA from Yunnan of China 260g, licorice 15g, fried atractylodes
260g, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China 120g, Ramulus Cinnamomi 60g and ginger slice 10g.
6. a kind for the treatment of diabetes B stagnation of turbid phlegm in middle-JIAO card and the turbid tune sugar-pill of middle drop, feature according to claim 1 exist
In: it is prepared using following Chinese medicine material: Rhizoma Alismatis 290g, umbellate pore furgus 275g, PORIA from Yunnan of China 275g, licorice 25g, fried atractylodes
275g, rhizoma atractylodis macrocephalae 260g, citrus chachiensis hortorum 90g, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China 120g, Ramulus Cinnamomi 60g and ginger slice 20g.
7. based on a kind of described in any item the treat diabetes B stagnation of turbid phlegm in middle-JIAO card and turbid tune sugar-pills of middle drop of claim 1~6
Preparation method, comprising the following steps:
Step 1: Rhizoma Alismatis, umbellate pore furgus, PORIA from Yunnan of China and all medicines of licorice being put into baking oven, 75 DEG C dry 12 hours, after mixing
It is spare to be ground into 80 mesh fine powders；
Step 2: fried atractylodes, rhizoma atractylodis macrocephalae, citrus chachiensis hortorum, CORTEX MAGNOLIAE OFFICINALIS from Sichuan of China, Ramulus Cinnamomi and all medicine mixing and water addings of ginger slice being decocted three times, decocted
Liquid merges filtration, and filtrate is concentrated into clear cream, mixes with step 1 gained fine powder and squeeze pill after mixing cream, polishing is drying to obtain.
8. a kind of preparation side for treating the turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle according to claim 7
Method, it is characterised in that: decocted in step 2 three times specifically: it is 2 hours that the 1st time, which decocts, and the 2nd decoction and the 3rd decoction are
1 hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811603646.3A CN109498788A (en) | 2018-12-26 | 2018-12-26 | It is a kind of to treat turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811603646.3A CN109498788A (en) | 2018-12-26 | 2018-12-26 | It is a kind of to treat turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109498788A true CN109498788A (en) | 2019-03-22 |
Family
ID=65755466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811603646.3A Pending CN109498788A (en) | 2018-12-26 | 2018-12-26 | It is a kind of to treat turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109498788A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114617924A (en) * | 2021-06-25 | 2022-06-14 | 北京精医和生梅奥中医诊所有限公司 | Composition for treating type 2 diabetes |
-
2018
- 2018-12-26 CN CN201811603646.3A patent/CN109498788A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 庞国明: "纯中药治疗2型糖尿病临床研究"序贯三法"临床应用", 《中华中医药学会糖尿病分会2017年学术年会暨第十八次中医糖尿病大会论文汇编》 * |
| 庞国明等: "痰浊中阻臃肿胖 和中降浊调血糖", 《中国中医药报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114617924A (en) * | 2021-06-25 | 2022-06-14 | 北京精医和生梅奥中医诊所有限公司 | Composition for treating type 2 diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103566350B (en) | A kind of pharmaceutical composition with hypoglycemic effect | |
| CN102028900B (en) | Traditional Chinese medicine for treating metabolic syndrome and preparation method thereof | |
| CN100493572C (en) | Composition of medication for treating diabetes | |
| CN104491342A (en) | Medicament for treating diabetes and preparation method thereof | |
| CN102861201B (en) | Medicine composition for treating diabetes and preparation method thereof | |
| CN101513492A (en) | Chinese medicament for treating diabetes | |
| CN100579394C (en) | Rice conjee for treating diabetes | |
| CN109498788A (en) | It is a kind of to treat turbid tune sugar-pill of drop that diabetes B stagnation of turbid phlegm in middle-JIAO is demonstrate,proved and middle and preparation method thereof | |
| CN106421581A (en) | Biological traditional Chinese medicine for oral administration for treating diabetes and preparation method thereof | |
| CN102488846A (en) | Medicinal composition for treating diabetes mellitus | |
| CN104857436A (en) | Chinese herbal compound composition with anti-hepatoma activity as well as preparation method and application of Chinese herbal compound composition | |
| CN101843843A (en) | Chinese medicament for treating diabetes | |
| CN104367753A (en) | Traditional Chinese medicine composition for treating type 2 diabetes | |
| CN103990009A (en) | Traditional Chinese medicine for treatment of type II diabetes by invigorating spleen and purging turbidness | |
| CN103550335B (en) | Traditional Chinese medicinal composition for improving liver function | |
| CN102114185B (en) | Medicament for treating insulin resistance of type 2 diabetes | |
| CN105055967A (en) | Compound health care product having auxiliary blood sugar reducing function and preparation method | |
| CN104225016A (en) | Drug composition for treating spleen and stomach deficiency type chronic atrophic gastritis | |
| CN104740345B (en) | Treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN109395045A (en) | A kind of clearing away heat and eliminating dampeness tune sugar-pill and preparation method thereof for treating diabetes B MIDDLE ENERGIZER DAMPNESS-HEAT | |
| CN102380017A (en) | Medicament for treating diabetes and preparation method of medicament | |
| CN1181876C (en) | Medicine for curing diabetes and its preparing method | |
| CN117018105B (en) | Traditional Chinese medicine composition for treating impaired glucose tolerance and preparation method thereof | |
| CN1318042C (en) | Application of barbat skullcap in preparing medication for treating diabetes | |
| CN109157617B (en) | A Chinese medicinal composition for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190322 |
|
| RJ01 | Rejection of invention patent application after publication |